Home NDC 0002-8235-01 NDC 0002-8235-01 - LYUMJEV This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
Product NDC 0002-8235
Requested NDC 0002-8235-01
Package NDCs from labels 0002-8235-01, 0002-8235-05, 0002-8235-99
Manufacturer Eli Lilly and Company
Effective date 2026-06-16
Current FDA listing Not matched in FDA.report NDC product tables DailyMed Labels# Label, Manufacturer, Effective date table Label Manufacturer Effective date Type LYUMJEV - Eli Lilly and Company Eli Lilly and Company 2026-06-16 HUMAN PRESCRIPTION DRUG LABEL
DailyMed Package Descriptions# Package NDC, Product, Description table Package NDC Product Description Form Quantity Strength SPL version 0002-8235-01 LYUMJEVTempo Pen 3 mL in 1 SYRINGE INJECTION, SOLUTION 3 11 0002-8235-05 LYUMJEVTempo Pen 5 in 1 CARTON INJECTION, SOLUTION 5 11 0002-8235-99 LYUMJEVTempo Pen 3 mL in 1 SYRINGE INJECTION, SOLUTION 3 11 0002-8235-99 LYUMJEVTempo Pen 1 in 1 CARTON INJECTION, SOLUTION 1 11
DailyMed Dashboard NDC Coverage# NDC, Dashboard title, SPL version table NDC Dashboard title SPL version Validation Dashboard ZIP 0002-8235 LYUMJEV (INSULIN LISPRO-AABC) INJECTION, SOLUTION LYUMJEV KWIKPEN (INSULIN LISPRO-AABC) INJECTION, SOLUTION LYUMJEV JUNIOR KWIKPEN (INSULIN LISPRO-AABC) INJECTION, SOLUTION LYUMJEV TEMPO PEN (INSULIN LISPRO-AABC) INJECTION, SOLUTION LYUMJEV KWIKPEN (INSULIN LISPRO-AABC) INJECTION, SOLUTION [ELI LILLY AND COMPANY] 10 Current NDC, Legacy NDC, 4 package rows 20241027_c5a056e2-b568-4ca6-9ed8-79c010942d00.zip
openFDA label cross-check# OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
Matched openFDA labels page 47 of 235 · 4,682 matching rows.
Reported adverse events (FAERS/openFDA)# Adverse event summaries are temporarily unavailable. Other product information remains available.